Seasoned medtech leader with a proven track record in scaling companies
Oxford, UK – 7 November 2022 – OxSonics Therapeutics, a clinical-stage company focused on transforming cancer treatment through SonoTran®, its ultrasound-based drug delivery platform, announces that it has appointed Jérôme Marzinski as its Chief Executive Officer with immediate effect.
Jérôme is a seasoned medtech leader, having held a variety of senior roles over a more than 25 year career, with significant experience in scaling venture capital and private equity-funded businesses in the sector, having completed 15 M&A transactions and raised over €50m of growth capital.
Jérôme is an independent Board member of Cimon Medical, a Norwegian ultrasound specialist focusing on cerebral blood flow monitoring, where he was also the Interim Chief Executive Officer from January 2022, helping secure CE mark clearance for the Company’s lead product under new Medical Device Regulations. Prior to this, he spent three years as Chief Executive Officer at Visiometrics, an ophthalmic diagnostic company, that has developed and commercialized a breakthrough diagnostic for vision impairment and cataract detection. There, he oversaw a threefold increase in revenues, led the US commercial launch of a new product and completed the trade sale of the company’s asset to Keeler UK. He also spent six years in senior positions at ev3, which was sold to Covidien in 2012, and served as Chief Operating Officer of Vexim as it sourced a $15m Series C financing.
He is an independent Board member and strategic advisor to life sciences start-up Aniling and also owns MedCape Advisors, a management consulting agency for life sciences companies, providing advice on go-to-market strategy as well as international expansion.
Jérôme has an MA in corporate financing and accounting from the University of Lille, and in 2012 completed theTRIUM Global Executive MBA, jointly issued by New York University Stern School of Business, London School of Economics and Political Science, and HEC Paris School of Management.
Dr Allison Jeynes, Non-Executive Chair of OxSonics, said:
“We are delighted to welcome Jérôme to OxSonics. He is an experienced business leader who brings a wealth of relevant international sector knowledge, and a proven track record in leading medtech companies. His extensive experience of both capital raises and the commercial launch of products, will be invaluable as we continue to execute our growth strategy, expanding the clinical use of SonoTran® and building a broad pipeline of combinations.”
Jérôme Marzinski, Chief Executive Officer of OxSonics, said:
“I am excited by the opportunity to lead OxSonics. I have been very impressed by both the calibre of the team and the potential of SonoTran® to transform cancer treatment and address the urgent need for new technologies to increase the tumor penetration of oncology drugs. Through our Phase I/IIa study, as well as the existing partnerships, the Company is approaching a number of key value inflection points. I look forward to working with the rest of the Board and management team to take OxSonics to the next stage of its development.”
|Jérôme Marzinski, Chief Executive Officer||+44 (0)1865 784777|
|Walbrook PR (media enquiries)Stephanie Cuthbert / Phillip Marriage||+44 (0) 20 7933 8780 or firstname.lastname@example.org|
+44 (0)7796 794 663
About OxSonics Therapeutics
OxSonics is a clinical-stage therapeutics company, transforming cancer treatment by harnessing its first-in-class, proprietary technology platform SonoTran® to enhance the delivery and improve the efficacy of oncology drugs.
Current oncology drugs are restricted by their poor ability to penetrate solid tumors.
SonoTran® is being developed to provide a step-change in the therapeutic index of the drugs without the development costs or delays associated with drug reformulation. It combines Particles that are co-administered independently with an anti-cancer drug, and activated by a novel ultrasound device, creating a localised pumping effect that increases the delivery and penetration of the anti-cancer drug throughout the tumor. SonoTran® is designed to increase the dose and distribution of anti-cancer agents within solid tumours, thereby increasing the efficacy and/or reducing the toxicity of these agents across the majority of the most challenging solid tumor cancers.
The approach has been specifically designed to fit seamlessly into existing oncology clinical workflows, and has the major advantage of enabling healthcare professionals to see-as-they-treat by providing vizualisation on-screen and in real time.
SonoTran® is currently being evaluated in a phase I/IIa proof of concept clinical study in patients with metastatic colorectal cancer with liver metastases.
The SonoTran® drug delivery platform is based on ground-breaking technological advances, originally invented at the University of Oxford’s Institute of Biomedical Engineering.
OxSonics is based in Oxford in the UK.
For more information please visit: www.oxsonics.com